DENGUE VIRUS VACCINE
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 25, 2017
app pub date -
Nov 21, 2016
filing date -
Nov 20, 2015
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Recombinant fusion proteins including a dengue virus EIII and an E2 subunit derived from a thermophilic bacterium are described. Also described are expression vectors including a polynucleotide that encodes the recombinant fusion protein and a promoter. Also described are vaccine compositions that include either the recombinant fusion protein, polynucleotide, or both. Also described are methods of generating an immune response to dengue virus serotype 2 comprising administering one or more of the disclosed vaccine compositions.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully